Q1 Earnings Forecast for ANRO Issued By HC Wainwright

Alto Neuroscience, Inc. (NYSE:ANRO) – Analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Alto Neuroscience in a research report issued on Thursday, April 2nd. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of ($0.78) for the quarter. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. HC Wainwright also issued estimates for Alto Neuroscience’s Q2 2027 earnings at ($0.85) EPS, Q3 2027 earnings at ($0.91) EPS and Q4 2027 earnings at ($0.90) EPS.

Other equities research analysts have also issued research reports about the stock. JonesTrading cut their target price on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. BTIG Research raised their price objective on shares of Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Robert W. Baird cut their price objective on Alto Neuroscience from $41.00 to $38.00 and set an “outperform” rating on the stock in a research report on Thursday, April 2nd. Wedbush reduced their target price on Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating on the stock in a report on Thursday, April 2nd. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $35.00 target price on shares of Alto Neuroscience in a research report on Monday, March 16th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Alto Neuroscience has a consensus rating of “Moderate Buy” and a consensus price target of $35.14.

Alto Neuroscience Trading Down 6.3%

Alto Neuroscience stock traded down $1.42 during mid-day trading on Tuesday, reaching $21.11. 108,239 shares of the company traded hands, compared to its average volume of 255,021. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.69. Alto Neuroscience has a 52-week low of $1.90 and a 52-week high of $25.17. The firm has a market capitalization of $674.46 million, a price-to-earnings ratio of -9.71 and a beta of 2.01. The firm’s 50 day moving average price is $19.40 and its 200 day moving average price is $15.09.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.11.

Institutional Investors Weigh In On Alto Neuroscience

Several hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC purchased a new stake in Alto Neuroscience in the first quarter worth about $52,000. Torren Management LLC bought a new stake in shares of Alto Neuroscience in the 4th quarter worth approximately $62,000. Invesco Ltd. purchased a new stake in shares of Alto Neuroscience in the 1st quarter worth approximately $67,000. Vanguard Personalized Indexing Management LLC grew its stake in shares of Alto Neuroscience by 13.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after buying an additional 2,055 shares during the last quarter. Finally, Bridgeway Capital Management LLC increased its position in Alto Neuroscience by 85.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after buying an additional 25,000 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.